Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorGUERLAIS, Marylene
dc.contributor.authorAQUIZERATE, Aurelie
dc.contributor.authorLIONNET, Arthur
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDAVELUY, Amelie
dc.contributor.authorDUVAL, Melanie
dc.contributor.authorGERARDIN, Marie
dc.contributor.authorISTVAN, Marion
dc.contributor.authorLAFORGUE, Edouard-Jules
dc.contributor.authorVICTORRI-VIGNEAU, Caroline
dc.date.accessioned2023-06-23T13:19:01Z
dc.date.available2023-06-23T13:19:01Z
dc.date.issued2023-05-03
dc.identifier.issn2296-2565 (Electronic) 2296-2565 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182791
dc.description.abstractEnINTRODUCTION: Nitrous oxide has become over the last few years a public health problem in many countries. France has a dedicated health monitoring system dedicated to the surveillance of the abuse, dependence and consequences associated with the use of psychoactive substances coordinated by the French National Agency for the Safety of Medicines and Health Products.We present the French national survey of nitrous oxide. MATERIALS AND METHODS: We analyzed all the cases with nitrous oxide from 2012 to 2021: number of notifications, characteristics of the subjects and consumption, consequences reported and their evolutions over time. In addition, we have made a special focus on the four main complications reported. RESULTS: A total of 525 cases were received with an exponential increase since 2019. We observed changes in the characteristics of the notifications with an increase in the proportion of women [42.7% in 2021 vs. 30.8% in 2020 (p = 0.02)]; an increase in the quantities consumed (use of cylinders); a negative evolution of the contexts of use with a search for self-therapeutic effects and use in violent contexts; an increasing trend of the severity of cases [78.1% in 2021 vs. 70.0% in 2020 (p = 0.07)].The main effects were substance use disorders and/or associated criteria (82.5%), neurological disorders (75.4%), psychiatric symptoms (15.4%) and cardiovascular events (8.6%). In terms of evolution, we observed a significant increase in cases with a use disorder and an increase in neurological complications. Moreover, new serious effects, notably cardiovascular events were reported. DISCUSSION: The combination of high availability, varied effects from euphoria to relief of discomfort in a stressful global pandemic context and the development of dependence could explain the rapid growth of consumption and the seriousness of the cases.It must now be taken into account that (i) Substance use disorders are associated with nitrous oxide consumption; (ii) clinicians must consider "nitrous oxide" in young subjects presenting different types of manifestations; and (iii) stopping consumption is imperative and is the first treatment. In this context, an addictological assessment must also be carried out.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enNitrous oxide
dc.subject.enSubstance use disorder
dc.subject.enAddictovigilance
dc.subject.enPharmacodependence
dc.subject.enAddiction
dc.title.enNitrous oxide: a unique official French addictovigilance national survey
dc.title.alternativeFront Public Healthen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fpubh.2023.1167746en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37206871en_US
bordeaux.journalFrontiers in Public Healthen_US
bordeaux.page1167746en_US
bordeaux.volume11en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04139415
hal.version1
hal.date.transferred2023-06-23T13:19:17Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Public%20Health&rft.date=2023-05-03&rft.volume=11&rft.spage=1167746&rft.epage=1167746&rft.eissn=2296-2565%20(Electronic)%202296-2565%20(Linking)&rft.issn=2296-2565%20(Electronic)%202296-2565%20(Linking)&rft.au=GUERLAIS,%20Marylene&AQUIZERATE,%20Aurelie&LIONNET,%20Arthur&DAVELUY,%20Amelie&DUVAL,%20Melanie&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée